WAO - ARIA consensus on chronic cough: Executive summary
- PMID: 40093560
- PMCID: PMC11903822
- DOI: 10.1016/j.waojou.2025.101034
WAO - ARIA consensus on chronic cough: Executive summary
Abstract
Acute cough is a highly prevalent symptom in clinical practice. Chronic cough is a complex disease with significant impact on quality of life. The mechanistic pathways of chronic cough in cough-comorbid clinical phenotypes are elusive. Mounting evidence suggests presence of a hypersensitive cough reflex and implication of transient receptor potential channels and P2X receptors in cough neuronal pathways. Previously, the World Allergy Organization (WAO)/Allergic Rhinitis and its Impact on Asthma (ARIA) Joint Committee on Chronic Cough published updated experimental and clinical data on chronic cough, in addition to a multidisciplinary care pathway approach to its management. The goal of this manuscript is to provide clinicians with a succinct summary of chronic cough pathophysiology, clinical phenotypes, and management strategies in both primary and cough specialty care. This executive summary is a primer for clinicians on chronic cough. Increasing awareness on the topic among primary care physicians will improve the outcome of management of patients with chronic cough.
Keywords: Chronic cough; Gastroesophageal reflux disease; Hypersensitive cough reflex; Lower airway disease; Multifactorial chronic cough; Neuromodulators; Primary care physician; Refractory chronic cough; Unexplained chronic cough; Upper airway disease.
© 2025 The Authors.
Conflict of interest statement
Talal Nsouli: speaker for AstraZeneca. Jonathan A Bernstein: Merck and GSK related to chronic cough. Georges S Juvelekian: speaker for AstraZeneca, Abbott, Boehringer Ingelheim, Sanofi Aventis, Organon, Novartis, and Pfizer. Member of the Advisory board of AstraZeneca, Novartis, and Pfizer. Pete Smith: PI/Consultant GSK, Sanofi Regeneron, Viatris. Glenis Scadding: Honoraria for articles and speaker for GSK, advisory boards for GSK, ALK, Bayer, Chiesi, GlaxoSmithKline, Haleon, Noucor, Sanofi- Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Vice President, and AR lead for EUFOREA, and Chair/member Data Monitoring Committees on SLIT for ALK. Scientific Chief Editor, Rhinology Section, Frontiers in Allergy. L Klimek (LK) has received research grants from Allergy Therapeutics/Bencard, Great Britain/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden, Bionorica, Germany; BioNTech, Germany, Biomay, Austria, Boehringer Ingelheim, Germany, Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; MSD, USA, Viatris/Mylan, USA; Novartis, Switzerland, Leti, Spain; ROXALL, Germany; GlaxoSmithKline (GSK), Great Britain; Sanofi, France; Stallergenes, France; Thermofisher, USA and/or has served on the speaker's bureau or was consulting for the above mentioned pharmaceutical companies. Alessandro Fiocchi: Member of an advisory board: Abbott S.A., Danone, Ferrero SpA, Sponsored research: Ferrero SpA, Novartis S.A., Astrazeneca S.A, Vertex S.A., GSK S.A., Sanofi S.A., DVB S.A. Pedro Giavina-Bianchi: speaker and member for advisory board for: AstraZeneca, Abbvie, CSL Behring, GSK, Novartis, Sanofi, Takeda/Shire.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
